|
|
| (33 intermediate revisions by 9 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {| border="1" style="border-collapse:collapse" cellpadding="3" align="right" | | {| class="infobox" style="float:right;" |
| | colspan="3" align="center" bgcolor="#ABCDEF" | Conduction | | | [[File:Siren.gif|30px|link=Atrial fibrillation resident survival guide]]|| <br> || <br> |
| |-
| | | [[Atrial fibrillation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] |
| | <small>Sinus rhythm</small> [[Image:Heart conduct sinus.gif|none|75px]]
| |
| | <small>Atrial fibrillation</small> [[Image:Heart conduct atrialfib.gif|none|100px]] | |
| |} | | |} |
| {{Infobox_Disease |
| |
| Name = |
| |
| Image = |
| |
| Caption = |
| |
| DiseasesDB = 1065 |
| |
| ICD10 = {{ICD10|I|48||i|30}} |
| |
| ICD9 = {{ICD9|427.31}} |
| |
| ICDO = |
| |
| OMIM = |
| |
| MedlinePlus = 000184 |
| |
| }}
| |
| {{Atrial fibrillation}} | | {{Atrial fibrillation}} |
| {{CMG}}; '''Associate Editor(s)-In-Chief:''' {{CZ}}; [[Varun Kumar, M.B.B.S.]] | | {{CMG}}; '''Associate Editor(s)-In-Chief:''' {{CZ}}; [[Varun Kumar, M.B.B.S.]] {{Anahita}} |
| | |
| '''''Synonyms and related keywords:''''' AF, Afib, fib
| |
|
| |
|
| ==Overview== | | ==Overview== |
| Rhythm control methods include electrical and chemical [[cardioversion]]:<ref name="pmid16908781"/>
| | [[Cardioversion]] is a [[medical procedure]] by which an abnormally [[fast heart rate]] ([[tachycardia]]) or [[cardiac arrhythmia]] is converted to a [[Electrical conduction system of the heart|normal rhythm]]. When [[heart rate|rate control]] is not successful enough or when it is not able to improve the [[symptoms]] of [[patients]] [[cardioversion|rhythm control]] (either [[pharmacology|pharmacological]] or electrical) should be considered. [[Atrial fibrillation electrical cardioversion|Electrical cardioversion]] involves the restoration of normal [[heart rhythm]] through the application of a [[defibrillator]]. The [[pharmacology|pharmalogical]] method is performed with usage of [[medications]], such as [[amiodarone]], [[dronedarone]], [[procainamide]], [[ibutilide]], [[propafenone]] or [[flecainide]]. Whichever method of [[cardioversion]] is used, approximately 50% of [[patients]] [[relapse]] within one year, although the continued daily use of [[mouth|oral]] [[antiarrhythmic drugs]] may extend this period. |
| * ''Electrical cardioversion'' involves the restoration of normal heart rhythm through the application of a DC electrical shock.
| |
| * ''Chemical cardioversion'' is performed with drugs, such as [[amiodarone]], [[dronedarone]]<ref>{{cite journal |author=Singh BN, Connolly SJ, Crijns HJ, ''et al'' |title=Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter |journal=N. Engl. J. Med. |volume=357 |issue=10 |pages=987–99 |year=2007 |pmid=17804843 |doi=10.1056/NEJMoa054686}}</ref>, [[procainamide]], [[ibutilide]], [[propafenone]] or [[flecainide]].
| |
| | |
| The main risk of cardioversion is systemic embolization of a [[thrombus]] (blood clot) from the previously fibrillating left atrium. Cardioversion should not be performed without adequate anticoagulation in patients with more than 48 hours of atrial fibrillation. Cardioversion may be performed in instances of AF lasting more than 48 hours if a [[transesophogeal echocardiogram]] (TEE) demonstrates no evidence of clot within the heart.<ref name="pmid16908781"/>
| |
| | |
| Whichever method of cardioversion is used, approximately 50% of patient [[relapse]] within one year, although the continued daily use of oral antiarrhythmic drugs may extend this period. The key risk factor for relapse is duration of AF, although other risk factors that have been identified include the presence of structural heart disease, and increasing age.
| |
| | |
| ==ACCF/AHA/HRS 2011 Guidelines- Pharmacological Cardioversion of Atrial Fibrillation (DO NOT EDIT) <ref name="pmid16908781">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16908781 ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.] ''Circulation'' 114 (7):e257-354. [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177292 DOI:10.1161/CIRCULATIONAHA.106.177292] PMID: [http://pubmed.gov/16908781 16908781]</ref><ref name="pmid21382897">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2011) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=21382897 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.] ''Circulation'' 123 (10):e269-367. [http://dx.doi.org/10.1161/CIR.0b013e318214876d DOI:10.1161/CIR.0b013e318214876d] PMID: [http://pubmed.gov/21382897 21382897]</ref>==
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Administration of [[flecainide]], [[dofetilide]], [[propafenone]], or [[ibutilide]] is recommended for pharmacological [[cardioversion]] of [[AF]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])' <nowiki>"</nowiki>
| |
| |}
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm)
| |
| |-
| |
| |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Digoxin]] and [[sotalol]] may be harmful when used for pharmacological [[cardioversion]] of [[AF]] and are not recommended. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]]) <nowiki>"</nowiki>
| |
| |-
| |
| |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Quinidine]], [[procainamide]], [[disopyramide]], and [[dofetilide]] should not be started out of hospital for conversion of [[AF]] to [[sinus rhythm]].([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) <nowiki>"</nowiki>
| |
| |}
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| |-
| |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Administration of [[amiodarone]] is a reasonable option for pharmacological [[cardioversion]] of [[AF]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]]) <nowiki>"</nowiki>
| |
| |-
| |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' A single oral bolus dose of [[propafenone]] or [[flecainide]] (“pill-in-the-pocket”) can be administered to terminate persistent [[AF]] outside the hospital once treatment has proved safe in hospital for selected patients without sinus or [[AV node]] dysfunction, [[bundle branch block]], [[QT-interval prolongation]], the [[Brugada syndrome]], or [[structural heart disease]]. Before [[antiarrhythmic medication]] is initiated, a [[beta blocker]] or non [[dihydropyridine]] [[calcium channel antagonist]] should be given to prevent rapid AV conduction in the event [[atrial flutter]] occurs. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki>
| |
| |-
| |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' Administration of [[amiodarone]] can be beneficial on an outpatient basis in patients with paroxysmal or persistent [[AF]] when rapid restoration of [[sinus rhythm]] is not deemed necessary. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki>
| |
| |}
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
| |
| |-
| |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Administration of [[quinidine]] or [[procainamide]] might be considered for pharmacological [[cardioversion]] of [[AF]], but the usefulness of these agents is not well established. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki>
| |
| |}
| |
| | |
| ==ACCF/AHA/HRS 2011 Guidelines- Direct-Current Cardioversion of Atrial Fibrillation and Flutter (DO NOT EDIT) <ref name="pmid16908781">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16908781 ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.] ''Circulation'' 114 (7):e257-354. [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177292 DOI:10.1161/CIRCULATIONAHA.106.177292] PMID: [http://pubmed.gov/16908781 16908781]</ref><ref name="pmid21382897">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2011) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=21382897 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.] ''Circulation'' 123 (10):e269-367. [http://dx.doi.org/10.1161/CIR.0b013e318214876d DOI:10.1161/CIR.0b013e318214876d] PMID: [http://pubmed.gov/21382897 21382897]</ref>==
| |
| | |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' When a rapid ventricular response does not respond promptly to pharmacological measures for patients with [[AF]] with ongoing [[myocardial ischemia]], symptomatic [[hypotension]], [[angina]], or [[HF]], immediate R-wave synchronized [[direct-current cardioversion]] is recommended. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Immediate [[direct-current cardioversion]] is recommended for patients with [[AF]] involving [[pre-excitation]] when very rapid [[tachycardia]] or hemodynamic instability occurs. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) <nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' [[Cardioversion]] is recommended in patients without hemodynamic instability when symptoms of [[AF]] are unacceptable to the patient. In case of early relapse of [[AF]] after [[cardioversion]], repeated [[direct-current cardioversion]] attempts may be made following administration of [[antiarrhythmic medication]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki>
| |
| |}
| |
|
| |
|
| {|class="wikitable"
| | ==Cardioversion== |
| |- | | *When [[heart rate|rate control]] is not successful enough or when it is not able to improve the [[symptoms]] of [[patients]] [[cardioversion|rhythm control]] (either [[pharmacology|pharmacological]] or electrical) should be considered. <ref name="pmid34020968">{{cite journal| author=Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee| title=Atrial fibrillation: diagnosis and management-summary of NICE guidance. | journal=BMJ | year= 2021 | volume= 373 | issue= | pages= n1150 | pmid=34020968 | doi=10.1136/bmj.n1150 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34020968 }} </ref> |
| | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | | *[[cardioversion|Rhythm control]] methods include electrical and [[Chemical substance|chemical]] [[cardioversion]] ([[pharmacology|pharmacological]]):<ref name="pmid16908781">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16908781 ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.] ''Circulation'' 114 (7):e257-354. [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177292 DOI:10.1161/CIRCULATIONAHA.106.177292] PMID: [http://pubmed.gov/16908781 16908781]</ref><ref name='Shea2002'>{{cite journal|title=Cardioversion|journal= Circulation|year=2002|first=Julie B.|last=Shea|coauthors=William H. Maisel|volume=106|issue=22|pages=e176–8|doi=10.1161/01.CIR.0000040586.24302.B9|url=http://circ.ahajournals.org/cgi/content/full/106/22/e176|format=|accessdate=|pmid=12451016 }}</ref><ref>{{cite journal |author=Singh BN, Connolly SJ, Crijns HJ, ''et al'' |title=Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter |journal=N. Engl. J. Med. |volume=357 |issue=10 |pages=987–99 |year=2007 |pmid=17804843 |doi=10.1056/NEJMoa054686}}</ref> |
| |- | | ** [[Atrial fibrillation electrical cardioversion|Electrical cardioversion]] involves the restoration of normal [[heart rhythm]] through the application of a [[defibrillator]]. |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''[[Direct-current cardioversion]] can be useful to restore [[sinus rhythm]] as part of a long-term management strategy for patients with [[AF]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) <nowiki>"</nowiki> | | ** [[Atrial fibrillation pharmacological cardioversion|Chemical cardioversion]] is performed with usage of [[medications]], such as [[amiodarone]], [[dronedarone]], [[procainamide]], [[ibutilide]], [[propafenone]] or [[flecainide]]. |
| |- | | *In [[patients]] with [[atrial fibrillation]] more than 48 hours or even in cases that onset of [[atrial fibrillation]] is unknown it is recommended to delay [[cardioversion]] [[treatment]] until at least 3 weeks after [[anticoagulation]] [[therapy]].<ref name="pmid34020968">{{cite journal| author=Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee| title=Atrial fibrillation: diagnosis and management-summary of NICE guidance. | journal=BMJ | year= 2021 | volume= 373 | issue= | pages= n1150 | pmid=34020968 | doi=10.1136/bmj.n1150 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34020968 }} </ref> |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Patient preference is a reasonable consideration in the selection of infrequently repeated [[cardioversion]] for the management of symptomatic or recurrent [[AF]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki> | | *The main risk of [[cardioversion]] is [[systemic embolization]] of a [[thrombus]] ([[Thrombus|blood clot]]) from the previously fibrillating [[left atrium]]. [[Cardioversion]] should not be performed without adequate [[anticoagulation]] in [[patients]] with more than 48 hours of [[atrial fibrillation]]. [[Cardioversion]] may be performed in instances of [[atrial fibrillation]] lasting more than 48 hours if a [[transesophogeal echocardiogram]] ([[transesophogeal echocardiogram|TEE]]) demonstrates no evidence of [[clot]] within the [[heart]].<ref name="pmid16908781"/> |
| |}
| |
|
| |
|
| {|class="wikitable"
| | *Whichever method of [[cardioversion]] is used, approximately 50% of [[patients]] [[relapse]] within one year, although the continued daily use of [[mouth|oral]] [[antiarrhythmic drugs]] may extend this period. |
| |-
| | *The key [[risk factor]] for relapse is duration of [[atrial fibrillation]]. Other [[risk factors]] that have been identified include the presence of [[structural heart disease]], and [[old age]]. |
| |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm)
| |
| |-
| |
| |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Frequent repetition of [[direct-current cardioversion]] is not recommended for patients who have relatively short periods of [[sinus rhythm]] between relapses of [[AF]] after multiple [[cardioversion]] procedures despite prophylactic [[antiarrhythmic drug therapy]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki>
| |
| |-
| |
| |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Electrical [[cardioversion]] is contraindicated in patients with [[digitalis]] toxicity or [[hypokalemia]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]]) <nowiki>"</nowiki>
| |
| |}
| |
| | |
| ==ACCF/AHA/HRS 2011 Guidelines- Pharmacological Enhancement of Direct-Current Cardioversion (DO NOT EDIT) <ref name="pmid16908781">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16908781 ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.] ''Circulation'' 114 (7):e257-354. [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177292 DOI:10.1161/CIRCULATIONAHA.106.177292] PMID: [http://pubmed.gov/16908781 16908781]</ref><ref name="pmid21382897">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2011) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=21382897 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.] ''Circulation'' 123 (10):e269-367. [http://dx.doi.org/10.1161/CIR.0b013e318214876d DOI:10.1161/CIR.0b013e318214876d] PMID: [http://pubmed.gov/21382897 21382897]</ref>==
| |
| {{cquote|
| |
| ===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]===
| |
| '''1.''' Pretreatment with [[amiodarone]], [[flecainide]], [[ibutilide]], [[propafenone]], or [[sotalol]] can be useful to enhance the success of [[direct-current cardioversion]] and prevent recurrent [[atrial fibrillation]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
| |
| | |
| '''2.''' In patients who relapse to [[AF]] after successful [[cardioversion]], it can be useful to repeat the procedure following prophylactic administration of [[antiarrhythmic medication]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
|
| |
| ===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]===
| |
| '''1.''' For patients with persistent [[AF]], administration of [[beta blockers]], [[disopyramide]], [[diltiazem]], [[dofetilide]], [[procainamide]], or [[verapamil]] may be considered, although the efficacy of these agents to enhance the success of [[direct-current cardioversion]] or to prevent early recurrence of [[AF]] is uncertain. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
| | |
| '''2.''' Out-of-hospital initiation of [[antiarrhythmic medications]] may be considered in patients without [[heart disease]] to enhance the success of [[cardioversion]] of [[AF]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
| | |
| '''3.''' Out-of-hospital administration of [[antiarrhythmic medications]] may be considered to enhance the success of [[cardioversion]] of [[AF]] in patients with certain forms of [[heart disease]] once the safety of the drug has been verified for the patient. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''}}
| |
| | |
| ==ACCF/AHA/HRS 2011 Guidelines- Prevention of Thromboembolism in Patients With Atrial Fibrillation Undergoing Cardioversion (DO NOT EDIT) <ref name="pmid16908781">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16908781 ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.] ''Circulation'' 114 (7):e257-354. [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177292 DOI:10.1161/CIRCULATIONAHA.106.177292] PMID: [http://pubmed.gov/16908781 16908781]</ref><ref name="pmid21382897">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2011) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=21382897 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.] ''Circulation'' 123 (10):e269-367. [http://dx.doi.org/10.1161/CIR.0b013e318214876d DOI:10.1161/CIR.0b013e318214876d] PMID: [http://pubmed.gov/21382897 21382897]</ref>==
| |
| {{cquote|
| |
| ===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]===
| |
| '''1.''' For patients with [[AF]] of 48-h duration or longer, or when the duration of [[AF]] is unknown, [[anticoagulation]] ([[INR]] 2.0 to 3.0) is recommended for at least 3 week prior to and 4 wk after [[cardioversion]], regardless of the method (electrical or pharmacological) used to restore [[sinus rhythm]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
| |
| | |
| '''2.''' For patients with [[AF]] of more than 48-h duration requiring immediate [[cardioversion]] because of hemodynamic instability, [[heparin]] should be administered concurrently (unless contraindicated) by an initial intravenous bolus injection followed by a continuous infusion in a dose adjusted to prolong the [[activated partial thromboplastin time]] to 1.5 to 2 times the reference control value. Thereafter, oral [[anticoagulation]] ([[INR]] 2.0 to 3.0) should be provided for at least 4 wk, as for patients undergoing elective [[cardioversion]]. Limited data support subcutaneous administration of [[low molecular weight heparin]] in this indication. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
| | |
| '''3.''' For patients with [[AF]] of less than 48-h duration associated with hemodynamic instability ([[angina pectoris]], [[acute MI]], [[cardiogenic shock]], or [[pulmonary edema]]), [[cardioversion]] should be performed immediately without delay for prior initiation of [[anticoagulation]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
|
| |
| ===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]===
| |
| '''1.''' During the first 48 h after onset of [[AF]], the need for [[anticoagulation]] before and after [[cardioversion]] may be based on the patient’s risk of [[thromboembolism]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
| | |
| '''2.''' As an alternative to [[anticoagulation]] prior to [[cardioversion]] of [[AF]], it is reasonable to perform [[TEE]] in search of [[thrombus]] in the LA or LAA. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
| |
| | |
| ''':a.''' For patients with no identifiable [[thrombus]], [[cardioversion]] is reasonable immediately after [[anticoagulation]] with [[unfractionated heparin]] (e.g., initiate by intravenous bolus injection and an infusion continued at a dose adjusted to prolong the [[activated partial thromboplastin time]] to 1.5 to 2 times the control value until oral [[anticoagulation]] has been established with a [[vitamin K antagonist]] (e.g., [[warfarin]]), as evidenced by an [[INR]] equal to or greater than 2.0.). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' Thereafter, oral [[anticoagulation]] ([[INR]] 2.0 to 3.0) is reasonable for a total [[anticoagulation]] period of at least 4 wk, as for patients undergoing elective [[cardioversion]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' Limited data are available to support the subcutaneous administration of a [[low molecular weight heparin]] in this indication. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
| | |
| ''':b.''' For patients in whom [[thrombus]] is identified by [[TEE]], oral [[anticoagulation]] ([[INR]] 2.0 to 3.0) is reasonable for at least 3 week prior to and 4 week after restoration of [[sinus rhythm]], and a longer period of [[anticoagulation]] may be appropriate even after apparently successful [[cardioversion]], because the risk of [[thromboembolism]] often remains elevated in such cases. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
| |
| | |
| '''3.''' For patients with [[atrial flutter]] undergoing [[cardioversion]], [[anticoagulation]] can be beneficial according to the recommendations as for patients with [[AF]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''}}
| |
| | |
| ==Vote on and Suggest Revisions to the Current Guidelines==
| |
| * [[The Living Guidelines: Diagnosis and Management of Atrial Fibrillation | The AF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]]
| |
| | |
| ==Guideline Resources==
| |
| *[http://content.onlinejacc.org/cgi/reprint/48/4/e149.pdf ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation] <ref name="pmid16908781">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16908781 ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.] ''Circulation'' 114 (7):e257-354. [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177292 DOI:10.1161/CIRCULATIONAHA.106.177292] PMID: [http://pubmed.gov/16908781 16908781]</ref>
| |
| | |
| *[http://circ.ahajournals.org/content/123/10/e269.full.pdf 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation] <ref name="pmid21382897">Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2011) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=21382897 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.] ''Circulation'' 123 (10):e269-367. [http://dx.doi.org/10.1161/CIR.0b013e318214876d DOI:10.1161/CIR.0b013e318214876d] PMID: [http://pubmed.gov/21382897 21382897]</ref>
| |
| | |
| *[http://circ.ahajournals.org/content/117/8/1101.full.pdf ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter] <ref name="pmid18283199">Estes NA, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS et al. (2008) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18283199 ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society.] ''Circulation'' 117 (8):1101-20. [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.187192 DOI:10.1161/CIRCULATIONAHA.107.187192] PMID: [http://pubmed.gov/18283199 18283199]</ref>
| |
|
| |
|
| ==References== | | ==References== |
| {{reflist|2}} | | {{reflist|2}} |
| | |
| | {{WikiDoc Help Menu}} |
| | {{WikiDoc Sources}} |
| | [[CME Category::Cardiology]] |
|
| |
|
| [[Category:Electrophysiology]] | | [[Category:Electrophysiology]] |
| [[Category:Cardiology]] | | [[Category:Cardiology]] |
| [[Category:Emergency medicine]] | | [[Category:Emergency medicine]] |
|
| |
| [[de:Vorhofflimmern]]
| |
| [[fr:Fibrillation auriculaire]]
| |
| [[it:Fibrillazione atriale]]
| |
| [[nl:Boezemfibrilleren]]
| |
| [[ja:心房細動]]
| |
| [[no:Atrieflimmer]]
| |
| [[pl:Migotanie przedsionków]]
| |
| [[ro:Fibrilaţia Atrială]]
| |
| [[fi:Eteisvärinä]]
| |
| [[zh:心房颤动]]
| |
| [[tr:Atriyal fibrillasyon]]
| |
|
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
